METHOD OF QUANTITATIVE ASSESSMENT OF DEGREE OF CELLULAR PREPARATION RETENTION WITHIN TARGET ORGAN WHEN INTRAORGAN ADMINISTRATION USING RADIONUCLIDE METHOD Russian patent published in 2023 - IPC A61B6/00 G01T1/164 

FIELD: medicine; immuno-oncology.

SUBSTANCE: invention can be used to determine the relative amount of a cell preparation labeled with a radiopharmaceutical (RP) within the prostate gland. The eluate of ^99mTc-pertechnetate with an activity of 30 MBq per 1 ml of cell concentrate is combined with the lyophilisate of technefit, followed by addition to the cell concentrate, which is a leukothrombolayer obtained from 200 ml of the patient’s venous blood. The mixture is incubated for 5–10 minutes on a shuttle, after which it is centrifuged at 1162G with cooling for 10 minutes. The supernatant is removed using a plasma extractor. The resulting cell preparation, labeled with radiopharmaceuticals, is injected into the patient's prostate gland in a volume of 2 ml at a speed of 1 ml/30 sec under ultrasound control transrectally. Scintigraphy and SPECT/CT are performed in whole body mode 0.5, 12 and 24 hours after the introduction of a cell preparation labeled with radiopharmaceuticals into the prostate gland. The relative amount of a radiopharmaceutical-labeled cell preparation within the prostate gland is determined in % as the ratio of the radioactivity of the radiopharmaceutical-labeled cell preparation depot formed in the prostate gland 12 hours and 24 hours after the injection to the radioactivity of the radiopharmaceutical-labeled cell preparation depot formed in the prostate gland, 0.5 h after the injection.

EFFECT: method ensures the determination of the degree of retention of the cell preparation within the target organ during intraorgan administration of therapeutic cells using cells labeled with ^99mTc-technephyte in vitro, by determining the relative amount of the cell preparation labeled with radiopharmaceuticals within the prostate gland.

1 cl, 7 dwg, 3 ex